First dose completed in phase 1 cannabinoid study
27th July 2023 Uncategorised 0OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
More: First dose completed in phase 1 cannabinoid study
Source: News
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
More: First dose completed in phase 1 cannabinoid study
Source: News
© 1994 - 2024 B.M. Pharmaceuticals